

- **Manuscript type:** Research Article

Title page

Role of Hemogram-Derived Ratios and Systemic-Immune Inflammation Index in Prediction of COVID-19 Progression in Egyptian Patients

Running title: Hemogram Ratios in COVID-19 Progression.

Authors:

Sara I. Taha^{a*}, *Sara F. Samaan*^b, *Shereen A. Baioumy*^c, *Aalaa K. Shata*^d, *Mariam K. Youssef*^a

- Department of Clinical Pathology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
- Department of Internal Medicine, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
- Department of Microbiology and Immunology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
- Department of Pulmonary Medicine, Faculty of Medicine, Ain Shams university, Cairo, Egypt.

Authors:

*Sara Ibrahim Taha**

Degree: MD Clinical Pathology/Immunology

Lecturer of Clinical Pathology/ Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

E-mail: dr_sara_ib@med.asu.edu.eg

Sara Farid Samaan

Degree: MD Internal Medicine

Lecturer of Internal Medicine, Faculty of Medicine, Ain Shams university, Cairo, Egypt.

E-mail: Dr.sara_farid@yahoo.com

Shereen Atef Baioumy

Degree: MD Microbiology and Immunology

Lecturer of Microbiology and Immunology, Zagazig University, Zagazig, Egypt.

Email: drshereenatef@yahoo.com

Aalaa Kamal Shata

Degree: MD Pulmonary medicine

Lecturer of Pulmonary Medicine, Faculty of Medicine, Ain Shams university, Cairo, Egypt.

E-mail: aalaashata@yahoo.com

Mariam Karam Youssef

Degree: MD Clinical Pathology/Hematology

Lecturer of Clinical Pathology/Hematology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.

E-mail: Dr.mariam_karam@hotmail.com

* Corresponding Author:

Sara Ibrahim Taha, MD, PhD

Lecturer of Clinical Pathology/ Immunology, Faculty of Medicine, Ain Shams University.

Address: Ain Shams University, Abassia, Cairo, Egypt

Office tel., fax: + (202) 24346308 Mobile: + (20) 1125360009

E-mail: dr_sara_ib@med.asu.edu.eg

<https://orcid.org/0000-0001-8224-8701>

1 **Abstract**

2 **Background:** Early detection of COVID-19 patients with potentially severe disease is
3 crucial for predicting the disease's course and prioritizing medical resources, lowering
4 overall disease mortality. **Objectives:** To explore the role of hemogram-derived ratios
5 and systemic-immune inflammation index (SII), in addition to C-reactive protein (CRP),
6 in predicting COVID-19 severity and prognosis. **Methods:** In this retrospective study,
7 data were collected from the medical records of 425 COVID-19 patients. Neutrophil-to-
8 lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and SII, together with the
9 CRP, were investigated and compared. **Results:** NLR, PLR, SII, and CRP increased
10 significantly in severe cases and with ICU admission ($p \leq 0.001$). But, in non-survivors
11 only NLR and CRP were significantly elevated ($p < 0.05$). By interpreting area under the
12 receiver operating characteristic curve (ROC-AUC), CRP and NLR were better
13 predictors of disease severity (AUC: 0.7 for both), the need for ICU admission (AUC:
14 0.763 and 0.727, respectively) and in-hospital mortality (AUC: 0.812 and 0.75,
15 respectively). SII was significantly associated with the risk of severe disease development
16 (odds ratio (OR): 3.143; 95% confidence interval (CI): 1.101-8.976); CRP (OR: 2.902;
17 CI95%: 1.342-6.273) and NLR (OR: 2.662; CI95%, 1.072-6.611) were significantly
18 associated with ICU admission risk; and only CRP was significantly associated with in-
19 hospital mortality risk (OR: 3.988; CI95%: 1.460-10.892). **Conclusions:** Values of CRP,
20 SII, and NLR at the time of hospital admission could be independent prognostic
21 biomarkers to predict COVID-19 progression. The integration of CRP, SII, and NLR into
22 prognostic nomograms may lead to improved prediction.

23 **Keywords:** Coronavirus; Inflammation index; Lymphocyte ratio; Mortality; Progression.

24 **INTRODUCTION:**

25 Fatal coronavirus, named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-
26 2), has caused novel corona virus disease (COVID-19) which first broke out in December
27 2019 in Wuhan, China [1]. Fever, dry cough, and fatigue are the main manifestations of
28 COVID-19. In more severe cases, patients often have dyspnea and/or hypoxemia that can
29 rapidly progress to acute respiratory distress syndrome, septic shock, metabolic acidosis,
30 coagulation dysfunction, and multiple organ failure [2].

31 Although the majority of COVID-19 patients have been classified as mild cases that can
32 recover shortly after appropriate clinical intervention, rapid severe progression of the
33 disease can occur with increasing rates of hospitalization, ICU admission and mortality
34 [3]. Furthermore, not all COVID-19 patients have symptoms in the early stage of the
35 disease, making early tracking of suspected cases very important [4]. Neither the
36 detection capability of viral nucleic acid kits nor the popular rate of pulmonary imaging
37 can support large-scale screening of all populations. In the current novel corona virus
38 pandemic, if the most routine and inexpensive peripheral blood tests have characteristic
39 changes for infected patients, especially those with severe infections, they will be very
40 helpful for proper early clinical intervention to reduce the mortality of patients. Complete
41 blood count (CBC) is the most widely performed, cost effective test that can be
42 performed in almost all laboratories, even in those with limited equipment [4].

43 In this study, the role of peripheral CBC derived biomarkers (NLR, PLR, SII) together
44 with the CRP at hospital admission, has been examined to predict the progression and the
45 outcome of COVID-19 infection in a cohort of Egyptian patients.

46

47 MATERIALS AND METHODS

48 Patient selection:

49 This retrospective study was conducted in line with research regulations, including the
50 approval of Ain-Shams University Faculty of Medicine Research Ethics Committee
51 (REC). Data were acquired anonymously from hospital records and kept private and
52 confidential. They were only used for study purposes.

53 We randomly selected 425 COVID-19 patients admitted to Quarantine Hospitals of Ain-
54 Shams University (El-Obour Ain Shams University Specialized Hospital and El-
55 demerdash Hospital), Cairo, Egypt, between February and April, 2021. COVID-19
56 infection was confirmed in all cases by a positive reverse transcription polymerase chain
57 reaction (RT-PCR) test result for nasal and pharyngeal swab specimens. Only patients
58 above the age of 18 years were included in the study. The study excluded pregnant
59 women and patients with aplastic anemia, lymphoproliferative or myeloproliferative
60 disorders, immune deficiency, and a history of taking drugs that affect blood cell counts
61 such as epinephrine, thyroxin, or corticosteroids.

62 Data collection:

63 Demographic and clinical data were collected from the medical records of the patients,
64 including: age, gender, clinical presentation, detailed medical and drug history, presence
65 of co-morbidities, need for ICU admission and patients' outcome. Also, on admission,
66 laboratory findings were collected and analyzed, including CBC with differential counts
67 and CRP. Blood cell ratios and indexes of systemic inflammation were calculated,

68 including: the NLR (neutrophil/lymphocyte ratio), PLR (platelet/lymphocyte ratio) and
69 SII ((neutrophils × platelets)/lymphocytes).

70 Categorization of patients was done in accordance with guidelines of Ain Shams
71 University Hospitals Consensus Statement on Management of Adult COVID-19 Patients
72 [5].

73 **Statistical analysis:**

74 Categorical variables were analyzed using the Chi-square test and were expressed as a
75 number and percentage. For analysis of the parametric variables, the independent samples
76 t-test was used and they were presented as a mean and standard deviation. Non-
77 parametric variables were analyzed by the Mann–Whitney U test and presented as the
78 median and interquartile range (IQR). The ROC curve analysis was used to assess the
79 predictive performance of the significant parameters. To analyze the association between
80 the COVID-19 severity, need for ICU admission or in-hospital mortality, and related
81 factors, univariate and multivariate analyses were carried out using a logistic regression
82 model. The statistical analysis of the data was performed using SPSS version 20.0
83 software. A p value of ≤ 0.05 was considered statistically significant.

84 **RESULTS**

85 **Demographic and clinical characteristics of the entire study cohort:**

86 A total of 425 adult patients (227 females and 198 males) with confirmed COVID-19
87 infection were included in this study. Of them, 188 (44.2%) patients were mild, while 237
88 (55.8%) were moderate/severe cases. The mean age was 47.90 ± 17.08 years.
89 Hypertension (34.1%) and diabetes (30.4%) were the most common co-morbidities. Only

90 112 (26.4%) patients required ICU admission. Of all studied subjects, 385 (90.6%)
91 patients were discharged alive, whereas the remaining 40 (9.4%) died. The median
92 hospitalization duration was 10 days (IQR: 6 – 17). The baseline characteristics of the
93 included patients are shown in **tables 1 (a) and 2 (a)**.

94 **Clinical variables associated with disease severity:**

95 **Table 1 (b)** summarizes the characteristics of the mild (n = 188) and moderate/severe (n
96 = 237) groups. The mean age of the moderate/severe group was significantly higher than
97 that of the mild group (53.47 years \pm 16.10 vs. 40.84 years \pm 15.65; $p < 0.05$), with no
98 statistically significant difference in gender between both groups ($p > 0.05$). Of the
99 moderate/severe group, 108 (45.6%) patients required ICU admission and 40 (16.9%)
100 patients died. In contrast, of the mild group, only 4 (2.1%) patients required ICU
101 admission and no deaths occurred. The moderate/severe group had a statistically
102 significant longer length of hospital stay when compared to the mild group (14 days
103 (IQR: 9 – 20) vs 7 days (IQR: 5 – 10), $p \leq 0.001$).

104 **Table 2 (b)** shows that co-morbidities including chronic obstructive pulmonary disease
105 (COPD), diabetes mellitus, hypertension, chronic liver disease, chronic kidney disease
106 and ischemic heart disease were significantly associated with disease severity ($P \leq 0.001$)

107 The moderate/severe group had statistically significant lower hemoglobin and
108 lymphocyte count but statistically significant higher total leukocytic count (TLC), PLR,
109 NLR, SII and CRP when compared to the mild group ($P < 0.05$). Platelet and neutrophil
110 counts were not significantly different between groups ($p > 0.05$). **Table 3 (b)**

111 **Clinical variables associated with ICU admission:**

112 The mean age of the ICU group (n=112) was significantly higher than that of the non-
113 ICU group (n=313) (56.83 years \pm 15.75 vs. 44.70 years \pm 16.41; $p \leq 0.001$), but no
114 statistically significant difference in gender was found between the groups ($p > 0.05$).
115 The ICU group had a statistically significant longer length of hospital stay when
116 compared to the non-ICU group (19 days (IQR: 9 – 22) vs 9 days (IQR: 6 – 13), $p \leq$
117 0.001). Of the ICU group, 108 (96.4%) patients were moderate/severe and 4 (3.6%)
118 patients were mild. Only 39 (34.8%) patients of the ICU group died. **Table 1 (c)**

119 All the previously mentioned co-morbidities were significantly associated with ICU
120 admission ($P \leq 0.001$) except chronic liver disease ($p > 0.05$). **Table 2 (c)**

121 Similar to the moderate/severe group, the ICU group had statistically significant lower
122 hemoglobin and lymphocyte count but statistically significant higher TLC, PLR, NLR,
123 SII and CRP when compared to the non-ICU group ($P \leq 0.001$). Platelet and neutrophil
124 counts were not significantly different between groups ($p > 0.05$). **Table 3 (c)**

125 **Clinical variables associated with in-hospital mortality:**

126 **Table 1 (d)** summarizes the demographic and clinical characteristics for survivors
127 (n=385) and non-survivors (n=40). Non-survivors were significantly older than survivors
128 (mean age: 60.30 years \pm 13.60 vs. 46.61years \pm 16.90; $p \leq 0.001$) with no significant
129 gender difference. They had a statistically significant longer length of hospital stay when
130 compared to survivors (18 days (IQR: 7 – 22) vs 10 days (IQR: 6 – 15), $p < 0.05$).

131 **Table 2 (d)** shows that chronic liver disease was not significantly associated with in-
132 hospital mortality ($p > 0.05$) but the other mentioned comorbidities did ($p < 0.05$).

133 Non-survivors had statistically significant higher TLC, NLR and CRP when compared to
134 the survivors ($P < 0.05$). Hemoglobin, platelet count, lymphocyte count, neutrophil count,
135 PLR and SII were not significantly different between groups ($p > 0.05$). **Table 3 (d)**

136 **Prediction of disease severity, ICU admission and in-hospital mortality:**

137 **Table 4** shows the independent prediction ability of the studied biomarkers and the
138 optimal cut-off values calculated by the ROC analysis. As regards COVID-19 severity
139 prediction, CRP AUC was 0.707 with a cut off value of 12 mg/L, sensitivity of 65.66%
140 and specificity of 69.31%, followed by NLR, SII and PLR with AUC of 0.700, 0.669 and
141 0.640, and cut-off values of 4.33, 1012.36 and 185, respectively. Regarding ICU
142 admission prediction, CRP AUC was 0.763 with a cut off value of 115 mg/L, sensitivity
143 of 54.76% and specificity of 94.30%., followed by NLR, SII and PLR with AUC of
144 0.727, 0.717 and 0.580, and cut-off values of 4.5, 668.57 and 300, respectively. For in-
145 hospital mortality prediction, CRP AUC was 0.812 with a cut off value of 141 mg/L,
146 sensitivity of 70% and specificity of 95.56%, followed by NLR with AUC of 0.751 and a
147 cut off value of 4.5. **Figures 1-3**

148 **Association with Disease Severity, ICU Admission and In-Hospital Mortality:**

149 To identify factors that may affect the disease severity, ICU admission or in-hospital
150 mortality, we obtained the odds ratios (OR) after conducting logistic regression analysis.
151 The multivariate analysis showed that SII (OR, 3.143; 95% CI, 1.101-8.976; $P < 0.05$)
152 was significantly positively associated with the disease severity, CRP (OR, 2.902; 95%
153 CI, 1.342-6.273; $P < 0.05$) and NLR (OR, 2.662; 95% CI, 1.072-6.611; $P < 0.05$) were
154 significantly positively associated with the need for ICU admission, and only CRP (OR,

155 3.988; 95% CI, 1.460-10.892; $P < 0.05$) was significantly positively associated with in-
156 hospital mortality. **Table 5**

157 **DISCUSSION**

158 Since hyper-inflammatory state has been incriminated in the patho-physiology of
159 COVID-19, information about inflammation and the immune response of patients with
160 different disease severity should be continuously explored for predicting the progression
161 of the disease and improving the outcome of patients [1]. Complete blood counts are the
162 most easily performed tests in a time and cost-effective manner. Included in the CBC are
163 values that can be used as effective inflammatory biomarkers [4].

164 Neutrophils can be triggered by virus-related inflammatory factors to release large
165 amounts of reactive oxygen species and other cytotoxic mediators, which may dampen
166 the virus. Moreover, neutrophils are able to release neutrophil extracellular traps that help
167 in capturing and damaging different pathogens, including viruses [6].

168 On the other hand, severe cases of viral infection can result in lymphocyte exhaustion,
169 because viruses can directly attack and damage target cells; also, they can activate
170 immune cells to participate in the anti-viral process, resulting in severe lymphocyte
171 damage and apoptosis. Because systemic inflammation stimulates neutrophil production
172 and accelerates lymphocyte apoptosis, virus-triggered inflammation raises the NLR ratio
173 [6].

174 Additionally, as platelets have an important role in the regulation of various
175 inflammatory processes, both the NLR and PLR indirectly reflect a patient's
176 inflammatory state [7]. In recent years, NLR and PLR have been validated as prognostic

177 biomarkers in various disorders including cardiac conditions, solid tumors, sepsis,
178 pneumonia, and acute respiratory distress syndrome [8].

179 A recently proposed score is the SII, which is an index defining the instability in the
180 inflammatory response. SII has been proposed as a prognostic indicator in the follow-up
181 of patients with sepsis and in a number of tumors including small cell lung and
182 hepatocellular carcinomas [7].

183 The current study is aimed at exploring the role of NLR, PLR, and SII, in addition to the
184 CRP in predicting severity of the disease, the need for ICU admission and in-hospital
185 mortality in COVID-19 patients.

186 We found a significant relation between advancing patients' ages and the severity of the
187 disease as well as the rate of ICU admission and in-hospital mortality. However, these
188 could not be linked to a specific gender. Our findings were consistent with the studies of
189 Yang et al. and Fois et al. [4],[9], who reported significantly advanced age and non-
190 significant difference in gender in the more severe cases and the non-survivors,
191 respectively. However, our study was only partially consistent with Wang and colleagues
192 [10] who reported non-significant differences in age or gender with the progression of the
193 disease. Similar to the study of Yang et al. [4], we found the overall incidence of co-
194 morbidities (diabetes, hypertension, kidney dysfunction) to be significantly higher in the
195 more severe cases. However, partially contrary to the study of Fois et al. [9], who found
196 only a significant association between heart disease and COVID-19 mortality and a non-
197 significant association between disease mortality and the other co-morbidities including
198 smoking, diabetes, and kidney disease, we found that in-hospital disease mortality was
199 significantly higher in patients with diabetes, hypertension, kidney and heart diseases.

200 Our study also showed a significant increase in NLR, PLR, SII, and CRP in the more
201 severe cases and in those who required ICU admission. However, only NLR and CRP
202 were significantly elevated in patients who died from the disease. This was in accordance
203 with the study of Yang and colleagues [4] who reported higher NLR, PLR and CRP in
204 the more severe cases of the disease. However, partially consistent with our study, Fois
205 and colleagues [9] reported significant elevation in NLR and SII in the non-survivor
206 group of the disease; they also reported that SII might specifically reflect the pulmonary
207 damage occurring in COVID-19 patients.

208 Our study revealed that the best cut-off points to predict disease severity and the need for
209 ICU admission were, CRP > 12mg/l & > 115mg/l, NLR > 4.33 & > 4.5, SII > 1012.36 &
210 > 668.57, and PLR > 185 & > 300, respectively. Also, the best cut-off points to predict
211 in-hospital mortality were CRP > 145mg/l and NLR > 4.5. In view of our data, 4 of the
212 188 included mild cases required ICU admission during their hospital stay. This resulted
213 in lowering the SII cut-off point of the need for ICU admission prediction compared to
214 that used to predict the disease severity. Furthermore, by multivariate regression analysis,
215 the SII was the best independent biomarker associated with disease severity; CRP and
216 NLR were the best independent predictors of the need for ICU admission; and only CRP
217 was significantly associated with the risk of in-hospital mortality. Yang and Co-workers
218 [4] found that both NLR and PLR were independent predictors of disease severity and
219 progression in their studied COVID-19 patients. Also, Fois and colleagues [9] found in
220 their study that the SII was the only independent biomarker to predict in-hospital
221 mortality of COVID-19 patients.

222 One limitation in our study was its retrospective design that could not keep up with the
223 dynamic nature of the disease; more prospective studies with serial determination of
224 biomarkers' levels at different disease stages are still required for better definition of the
225 cut off points that could predict the progression of the disease. our study was its
226 retrospective design that could not keep up with the dynamic nature of the disease; more
227 prospective studies with serial determination of biomarkers' levels at different disease
228 stages are still required for better definition of the cut off points that could predict the
229 progression of the disease.

230 **CONCLUSIONS:**

231 Elevated CRP, SII, and NLR were found to be independent prognostic biomarkers that
232 could predict COVID-19 progression. The integration of CRP, SII, and NLR into
233 prognostic nomograms may lead to improved prediction. While CRP along with other
234 inflammatory markers like ESR, LDH, ferritin, and procalcitonin are frequently measured
235 in COVID-19 patients, SII and NLR can be easily calculated using a differential CBC
236 and are cost effective, especially for third world countries.

237 **Abbreviations:**

238 *NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; RT-PCR, reverse*
239 *transcription polymerase chain reaction; SARS-CoV-2, severe acute respiratory*
240 *syndrome coronavirus-2; SII, systemic immune-inflammation index.*

241 **Manuscript word count:** 2515 words.

242 **Abstract word count:** 243 words

243 **Tables:** 5

244 **Figures:** 3

245 **Funding sources:** This research did not receive any specific grant from funding agencies
246 in the public, commercial, or not-for-profit sectors.

247 **Acknowledgement:** None.

248 **Conflicts of interest:** The authors declare that there is no conflict of interest regarding the
249 publication of this article.

250 **Consent for publication:** Not applicable.

251 **Availability of data and materials:** All data needed to support the current findings will be
252 available upon request.

253 **Author contributions:** *Sara I. Taha:* conceptualization, methodology, software; *Sara F.*
254 *Samaan and Aalaa K. Shata:* investigation, data collection. *Shereen A. Baioumy*
255 *visualization, supervision. Mariam K. Youssef:* writing- reviewing and editing, validation
256 and original draft preparation.

257 REFERENCES

258 [1] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. China Novel Coronavirus
259 Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in
260 China, 2019. *N Engl J Med.* 2020 Feb 20;382(8):727-733. doi:
261 10.1056/NEJMoa2001017. Epub 2020 Jan 24. PMID: 31978945; PMCID: PMC7092803.

262 [2] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical
263 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a

264 descriptive study. *Lancet*. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-
265 6736(20)30211-7. Epub 2020 Jan 30. PMID: 32007143; PMCID: PMC7135076.

266 [3] Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts
267 disease severity of COVID-19: a descriptive and predictive study. *Signal Transduct*
268 *Target Ther*. 2020 Mar 27;5(1):33. doi: 10.1038/s41392-020-0148-4. PMID: 32296069;
269 PMCID: PMC7100419.

270 [4] Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-
271 NLR and PLR in COVID-19 patients. *Int Immunopharmacol*. 2020 Jul; 84:106504. doi:
272 10.1016/j.intimp.2020.106504. Epub 2020 Apr 13. PMID: 32304994; PMCID:
273 PMC7152924.

274 [5] Abdelfattah AB, Ahmed S, El-Zahapy H, Al Said A, Salem S, Tharwat A, et al.
275 Hospital response to COVID-19 a consensus: Report on Ain Shams University Hospital
276 Strategy. [published online ahead of print, June 12, 2020]. *ScienceOpen*. doi:
277 <https://doi.org/10.14293/S2199-1006.1.SOR-.PPD4QZX.v1>

278 [6] Feng X, Li S, Sun Q, Zhu J, Chen B, Xiong M, Cao G. Immune-Inflammatory
279 Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis. *Front Med*
280 (Lausanne). 2020 Jun 9;7:301. doi: 10.3389/fmed.2020.00301. PMID: 32582743;
281 PMCID: PMC7295898.

282 [7] Usul E, Şan İ, Bekgöz B, Şahin A. Role of hematological parameters in COVID-19
283 patients in the emergency room. *Biomark Med*. 2020 Sep;14(13):1207-1215. doi:
284 10.2217/bmm-2020-0317. Epub 2020 Jul 21. PMID: 32692248; PMCID: PMC7372996.

- 285 [8] Chan AS, Rout A. Use of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte
286 Ratios in COVID-19. J Clin Med Res. 2020 Jul;12(7):448-453. doi: 10.14740/jocmr4240.
287 Epub 2020 Jun 25. PMID: 32655740; PMCID: PMC7331861.
- 288 [9] Fois AG, Paliogiannis P, Scano V, Cau S, Babudieri S, Perra R, et al. The Systemic
289 Inflammation Index on Admission Predicts In-Hospital Mortality in COVID-19 Patients.
290 Molecules. 2020 Dec 4;25(23):5725. doi: 10.3390/molecules25235725. PMID:
291 33291581; PMCID: PMC7731255.
- 292 [10] Wang C, Deng R, Gou L, Fu Z, Zhang X, Shao F, et al. Preliminary study to identify
293 severe from moderate cases of COVID-19 using combined hematology parameters. Ann
294 Transl Med. 2020 May;8(9):593. doi: 10.21037/atm-20-3391. PMID: 32566620; PMCID:
295 PMC7290538

296 **Table 1:** Comparisons of patient demographic and clinical characteristics according to COVID-
 297 19 severity, ICU admission and in-hospital mortality.

Variable	(a) Total (n=425)	(b)Severity			(c)ICU admission			(d) In-hospital mortality			
		Mild (n= 188)	Moderate to severe (n = 237)	P- value	Non-ICU (n =313)	ICU (n=112)	P- value	Survivors (n=385)	Non- survivors (n= 40)	P- value	
Age	Mean ± SD	47.90 ± 17.08	40.84± 15.65	53.47± 16.10	≤ 0.001	44.70± 16.41	56.83 ± 15.75	≤ 0.001	46.61± 16.90	60.30 ± 13.60	≤ 0.001
	Range	13 – 94	13 – 94	17 – 92		13 – 94	22 – 91		13 – 94	35 – 85	
Sex	Female	227 (53.4%)	110 (58.5%)	117 (49.4%)	0.061	174 (55.6%)	53 (47.3%)	0.132	205 (53.2%)	22 (55.0%)	0.832
	Male	198 (46.6%)	78 (41.5%)	120 (50.6%)		139 (44.4%)	59 (52.7%)		180 (46.8%)	18 (45.0%)	
Severity	Mild	188 (44.2%)				184 (58.8%)	4 (3.6%)	≤ 0.001	188 (48.8%)	0 (0.0%)	≤ 0.001
	Moderate to Severe	237 (55.8%)			129 (41.2%)	108 (96.4%)	197 (51.2%)		40 (100.0%)		
Hospital stay (days)	Median (IQR)	10 (6 – 17)	7 (5 – 10)	14 (9 – 20)	≤ 0.001	9 (6 – 13)	19 (9 – 22)	≤ 0.001	10 (6 – 15)	18 (7 – 22)	0.018
	Range	0 – 51	0 – 36	1 – 51		0 – 51	1 – 40		0 – 51	1 – 29	
ICU	Negative	313 (73.6%)	184 (97.9%)	129 (54.4%)	≤ 0.001				312 (81.0%)	1 (2.5%)	≤ 0.001
	Positive	112 (26.4%)	4 (2.1%)	108 (45.6%)		73 (19.0%)	39 (97.5%)				
Fate	Discharged	385 (90.6%)	188 (100%)	197 (83.1%)	≤ 0.001	312 (99.7%)	73 (65.2%)	≤ 0.001			
	Death	40 (9.4%)	0 (0.0%)	40 (16.9%)		1 (0.3%)	39 (34.8%)				

298

ICU, intensive care unit. Statistical significance set at 0.05.

299 **Table 2:** Comparisons of patient comorbidities according to COVID-19 severity, ICU admission
 300 and in-hospital mortality

Comorbidity	(a) Total (n=425)	(b)Severity			(c)ICU admission			(d) In-hospital mortality		
		Mild (n= 188)	Moderate to severe (n = 237)	P-value	Non-ICU (n =313)	ICU (n=112)	P-value	Survivors (n=385)	Non-survivors (n= 40)	P-value
COPD	78 (18.4%)	15 (8.0%)	63 (26.6%)	≤ 0.001	43 (13.7%)	35 (31.3%)	≤ 0.001	65 (16.9%)	13 (32.5%)	0.015
DM	129 (30.4%)	22 (11.7%)	107 (45.1%)	≤ 0.001	67 (21.4%)	62 (55.4%)	≤ 0.001	102 (26.5%)	27 (67.5%)	≤ 0.001
HTN	145 (34.1%)	26 (13.8%)	119 (50.2%)	≤ 0.001	80 (25.6%)	65 (58.0%)	≤ 0.001	119 (30.9%)	26 (65.0%)	≤ 0.001
CLD	17 (4.0%)	0 (0.0%)	17 (7.2%)	≤ 0.001	11 (3.5%)	6 (5.4%)	0.393	16 (4.2%)	1 (2.5%)	0.611
CKD	27 (6.4%)	2 (1.1%)	25 (10.5%)	≤ 0.001	13 (4.2%)	14 (12.5%)	0.002	20 (5.2%)	7 (17.5%)	0.002
IHD	42 (9.9%)	1 (0.5%)	41 (17.3%)	≤ 0.001	16 (5.1%)	26 (23.2%)	≤ 0.001	32 (8.3%)	10 (25.0%)	0.001

301 *COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HTN, hypertension; CLD,*
 302 *chronic liver disease; CKD, chronic kidney disease; IHD, ischemic heart disease. Statistical*
 303 *significance set at 0.05.*

304 **Table 3:** Comparisons of patient laboratory findings according to COVID-19 severity, ICU

305 admission and in-hospital mortality

Variable	(a)Total (n=425)	(b)Severity			(c) ICU admission			(d) In-hospital mortality		
		Mild (n= 188)	Moderate to severe	P-value	Non-ICU (n =313)	ICU (n=112)	p-value	Survivors (n=385)	Non-survivors (n= 40)	P -value
HB gm/dl	Mean ± SD	12.01 ± 2.34	12.39 ± 2.19	11.70 ± 2.42	12.25 ± 2.23	11.32 ± 2.51	≤ 0.001	12.08 ± 2.32	11.33 ± 2.43	0.055
	Range	2.9 – 17.3	5 – 17.3	2.9 – 16.6	5 – 17.3	2.9 – 16		2.9 – 17.3	6.6 – 16	
PLT ×10 ³ µl	Mean ± SD	248.02 ± 106.49	247.43 ± 90.64	248.49 ± 117.75	244.57 ± 96.21	257.66 ± 131.06	0.265	247.69 ± 104.01	251.13 ± 129.51	0.846
	Range	6 – 716	22 – 546	6 – 716	22 – 716	6 – 650		11 – 716	6 – 633	
TLC ×10 ³ µl	Median (IQR)	6.5 (4.5 – 9.8)	5.90 (4.46 – 7.63)	7.00 (4.62 – 11.30)	6.00 (4.40 – 8.30)	8.85 (5.05 – 13.50)	≤ 0.001	6.20 (4.40 – 9.18)	11.50 (5.75 – 15.90)	≤ 0.001
	Range	1.02 – 99.8	2.20 – 28.70	1.02 – 99.80	1.02 – 79.00	1.10 – 99.80		1.02 – 79.00	3.30 – 99.80	
PNL ×10 ³ µl	Median (IQR)	3.15 (2.2 – 4.9)	3.30 (2.46 – 4.30)	3.08 (2.10 – 5.70)	3.10 (2.20 – 4.40)	3.57 (1.90 – 9.05)	0.155	3.10 (2.20 – 4.60)	4.04 (2.10 – 11.50)	0.126
	Range	0.5 – 34.8	0.89 – 9.64	0.50 – 34.80	0.51 – 23.30	0.50 – 34.80		0.50 – 24.80	0.90 – 34.80	
LYMPH ×10 ³ µl	Median (IQR)	1.4 (0.9 – 2.08)	1.80 (1.30 – 2.30)	1.10 (0.70 – 1.60)	1.50 (1.10 – 2.20)	0.95 (0.70 – 1.40)	≤ 0.001	1.40 (0.90 – 2.10)	1.20 (0.78 – 1.60)	0.076
	Range	0.1 – 12.36	0.20 – 12.36	0.10 – 6.60	0.10 – 12.36	0.10 – 5.40		0.10 – 12.36	0.20 – 5.40	
PLR	Median (IQR)	162.5 (110 – 268.89)	134.67 (100.12 – 183.91)	213.75 (125.00 – 344.00)	148.57 (108.85 – 232.31)	254.58 (125.30 – 387.30)	≤ 0.001	160.77 (110.00 – 263.33)	192.26 (115.62 – 352.08)	0.212
	Range	3.7 – 1351.35	14.67 – 805.00	3.70 – 1351.35	8.33 – 1025.00	3.70 – 1351.35		8.33 – 1351.35	3.70 – 1055.00	
NLR	Median (IQR)	2.29 (1.5 – 4.17)	1.86 (1.25 – 2.77)	2.58 (1.75 – 6.92)	2.17 (1.38 – 3.38)	3.74 (1.75 – 9.75)	≤ 0.001	2.29 (1.46 – 4.00)	2.63 (1.70 – 11.03)	0.028
	Range	0.24 – 96.8	0.24 – 16.00	0.45 – 96.80	0.24 – 24.80	0.77 – 96.80		0.24 – 28.00	0.77 – 96.80	
SII	Median (IQR)	549 (308 – 965.45)	447.68 (280.35 – 718.95)	669.67 (348.92 – 1558.25)	507.50 (287.00 – 852.62)	737.55 (409.51 – 2117.54)	≤ 0.001	535.07 (304.33 – 937.44)	682.48 (371.61 – 2620.45)	0.056
	Range	11.45 – 15218.64	43.10 – 2576.00	11.45 – 15218.64	27.50 – 5580.00	11.45 – 15218.64		27.50 – 9632.00	11.45 – 15218.64	
CRP mg/L	Median (IQR)	24 (8 – 83)	12 (5 – 25)	64 (18 – 129)	16 (6 – 48)	103 (46 – 152)	≤ 0.001	20 (7 – 68)	125 (59 – 152)	≤ 0.001
	Range	1 – 710	2 – 164	1 – 710	1 – 372	1 – 710		1 – 710	1 – 352	

306 *HB, hemoglobin; PLT, platelets; TLC, total leucocytic count; PNL; neutrophils; LYMPH, lymphocytes;*
 307 *PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; SII, systemic immune-*
 308 *inflammation index (neutrophil*platelet to lymphocyte ratio); CRP, C-reactive protein. Statistical*
 309 *significance set at 0.05.*

310 **Table 4:** Recommended cut-off values for the prediction of COVID-19 severity, need for ICU
 311 admission and in-hospital mortality.


	AUC	Cut off	Sensitivity %	Specificity %	PPV %	NPV %
Disease severity						
PLR	0.640	>185	51.52	80.20	71.8	62.8
NLR	0.700	>4.33	47.47	95.05	89.1	62.3
SII	0.669	>1012.36	46.46	93.07	86.8	63.9
CRP (mg/L)	0.707	>12	65.66	69.31	67.7	67.3
ICU admission						
PLR	0.580	>300	38.10	89.87	50.0	84.5
NLR	0.727	>4.5	59.52	83.54	49.0	88.6
SII	0.717	>668.57	71.43	63.92	34.5	89.4
CRP (mg/L)	0.763	>115	54.76	94.30	71.9	88.7
In-hospital mortality						
NLR	0.751	>4.5	65.0	78.89	25.5	95.3
CRP (mg/L)	0.812	>141	70.0	95.56	63.6	96.6

312 *PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; SII, systemic immune-*
 313 *inflammation index (neutrophil*platelet to lymphocyte ratio); CRP, C-reactive protein; AUC, area*
 314 *under the curve; NPV, negative predictive value; PPV, positive predictive value.*

315 **Table 5:** Logistic regression analysis for predictors of COVID-19 severity, ICU admission and in-
 316 hospital mortality.

Disease severity	Uni-variate				Multi-variate			
	P-value	Odds ratio (OR)	95% C.I. for OR		P-value	Odds ratio (OR)	95% C.I. for OR	
			Lower	Upper			Lower	Upper
PLR	≤ 0.001	4.407	2.882	6.738	0.452	1.332	0.630	2.817
NLR	≤ 0.001	8.095	4.347	15.075	0.616	1.335	0.432	4.124
SII	≤ 0.001	7.808	4.191	14.547	0.032	3.143	1.101	8.976
CRP	≤ 0.001	6.017	3.893	9.300	0.166	1.533	0.837	2.808
ICU admission								
PLR	≤ 0.001	4.757	2.880	7.857	0.069	2.271	0.939	5.491
NLR	≤ 0.001	5.111	3.132	8.342	0.035	2.662	1.072	6.611
SII	≤ 0.001	2.195	1.416	3.401	0.067	0.414	0.161	1.062
CRP	≤ 0.001	7.617	4.465	12.995	0.007	2.902	1.342	6.273
In-hospital mortality								
NLR	0.001	3.273	1.673	6.403	0.766	1.149	0.461	2.863
CRP	≤ 0.001	10.332	5.024	21.248	0.007	3.988	1.460	10.892


317 *PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; SII, systemic immune-*
 318 *inflammation index (neutrophil*platelet to lymphocyte ratio); CRP, C-reactive protein; C.I,*
 319 *confidence interval. Statistical significance set at 0.05.*



320

321


Figure 1: Receiver-operating characteristic curve for prediction of disease severity



322

323

Figure 2: Receiver-operating characteristic curve for prediction of ICU admission



324

325

Figure 3: Receiver-operating characteristic curve for prediction of in-hospital mortality